Similar articles

• The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.

  Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. Kinder AJ, et al. Rheumatology (Oxford). 2005 Jan;44(1):61-6. doi: 10.1093/rheumatology/keh512. Rheumatology (Oxford). 2005. PMID: 15611303
• Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.

  Müller RB, von Kempis J, Haile SR, Schiff MH. Müller RB, et al. Semin Arthritis Rheum. 2015 Aug;45(1):28-34. doi: 10.1016/j.semarthrit.2015.02.009. Epub 2015 Mar 3. Semin Arthritis Rheum. 2015. PMID: 25895697
• Methotrexate: more questions than answers.

  Wallace CA. Wallace CA. J Rheumatol. 2000 Aug;27(8):1834-5. J Rheumatol. 2000. PMID: 10955320 No abstract available.
• [Methotrexate in rheumatology: a therapeutic revolution].

  Kaye O, Ribbens C, Hauwaert C, Malaise MG. Kaye O, et al. Rev Med Liege. 1995 Nov;50(11):453-7. Rev Med Liege. 1995. PMID: 8532990 Review. French. No abstract available.
• Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients.

  Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Kivity S, et al. Autoimmun Rev. 2014 Nov;13(11):1109-13. doi: 10.1016/j.autrev.2014.08.027. Epub 2014 Aug 27. Autoimmun Rev. 2014. PMID: 25172240 Review.